Logotype for Spruce Biosciences Inc

Spruce Biosciences (SPRB) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Spruce Biosciences Inc

Q3 2026 earnings summary

9 Nov, 2026

Executive summary

  • Q3 2026 net loss widened to $24.0m from $8.2m a year earlier, driven by higher TA-ERT development and manufacturing spending.

  • TA-ERT BLA submission for MPS IIIB remains on track for December 2026, seeking accelerated approval based on CSF HS-NRE reduction as a reasonably likely surrogate endpoint.

  • CRHX-101 assets and liabilities were transferred to Adrenyx in November; a pro rata shareholder distribution is planned for H1 2027, subject to conditions.

Financial highlights

  • Q3 operating expenses were $24.0m vs. $8.2m YoY; R&D was $18.1m vs. $5.0m and G&A was $5.8m vs. $3.2m.

  • 9M operating expenses were $52.5m vs. $25.4m; R&D was $37.9m vs. $15.4m and G&A was $14.6m vs. $10.0m.

  • 9M net loss was $52.5m vs. $24.3m, or $23.71 vs. $41.25 per share; Q3 loss per share was $8.51 vs. $14.58.

  • 9M operating cash use was $44.6m vs. $26.9m; financing provided $83.5m, primarily from the April offering, August private placement and Avenue loans.

Outlook and guidance

  • TA-ERT BLA submission seeking accelerated approval is anticipated in December 2026; potential U.S. commercial launch is in 2027 if approved.

  • Second TA-ERT PPQ batch and Transform confirmatory study are expected to begin in December 2026; the first PPQ batch, completed in July, is planned for the BLA.

  • Transform is expected to enroll ~14 children ages 1–5 with severe MPS IIIB; the U.S. open-label EAP began in November and is expected to enroll ~10 children.

  • Cash of $87.7m was expected to fund planned operations and debt obligations into 2H 2027; separately, the filing cited insufficient funding for 12 months absent alternative financing and substantial doubt about going concern.

  • R&D spending is expected to rise as TA-ERT advances through BLA review, the confirmatory study and potential approval; commercial and manufacturing capabilities are also planned to expand.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Spruce Biosciences